GB201114051D0 - Compounds and their uses - Google Patents

Compounds and their uses

Info

Publication number
GB201114051D0
GB201114051D0 GBGB1114051.4A GB201114051A GB201114051D0 GB 201114051 D0 GB201114051 D0 GB 201114051D0 GB 201114051 A GB201114051 A GB 201114051A GB 201114051 D0 GB201114051 D0 GB 201114051D0
Authority
GB
United Kingdom
Prior art keywords
ikke
tbk1
cancer
regulator
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1114051.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Domainex Ltd
Original Assignee
Domainex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domainex Ltd filed Critical Domainex Ltd
Priority to GBGB1114051.4A priority Critical patent/GB201114051D0/en
Publication of GB201114051D0 publication Critical patent/GB201114051D0/en
Priority to PCT/GB2012/051978 priority patent/WO2013024282A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The invention provides a compound that is an inhibitor of one or both of TBK1 and IKKe, or a down-regulator of the expression of one or both of TBK1 and IKKe, for use in a method of treating a cancer that is dependent on the PI3kinase pathway. The invention further provides a method of treating cancer in an individual in whom the cancer is dependent on the PI3kinase pathway, comprising administering to the individual a compound that is an inhibitor of one or both of TBK1 and IKKe, or a down-regulator of the expression of one or both of TBK1 and IKKe.
GBGB1114051.4A 2011-08-15 2011-08-15 Compounds and their uses Ceased GB201114051D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1114051.4A GB201114051D0 (en) 2011-08-15 2011-08-15 Compounds and their uses
PCT/GB2012/051978 WO2013024282A2 (en) 2011-08-15 2012-08-14 Compounds and their uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1114051.4A GB201114051D0 (en) 2011-08-15 2011-08-15 Compounds and their uses

Publications (1)

Publication Number Publication Date
GB201114051D0 true GB201114051D0 (en) 2011-09-28

Family

ID=44764528

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1114051.4A Ceased GB201114051D0 (en) 2011-08-15 2011-08-15 Compounds and their uses

Country Status (2)

Country Link
GB (1) GB201114051D0 (en)
WO (1) WO2013024282A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
HUE054031T2 (en) 2012-04-24 2021-08-30 Vertex Pharma Dna-pk inhibitors
GB201303109D0 (en) 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
HRP20211855T1 (en) 2013-03-12 2022-03-04 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
EP3013789B1 (en) 2013-06-28 2020-03-04 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
PL3057953T3 (en) 2013-10-17 2019-01-31 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
MA39186A1 (en) 2013-12-19 2017-11-30 Novartis Ag Derivatives of [1,2,4] triazolo [1,5-a] pyrimidine used as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
CN106061948A (en) 2014-01-15 2016-10-26 国家科学研究中心 Water soluble 4-azapodophyllotoxin analogs
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
NZ729618A (en) 2014-09-26 2018-07-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
JP2018505152A (en) 2014-12-23 2018-02-22 アン ブリンブル マーガレット Amino acid conjugates and peptide conjugates and uses thereof
CA2951911A1 (en) 2015-12-17 2017-06-17 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
EP3390387B1 (en) 2015-12-18 2021-11-17 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
EP3419962A4 (en) 2016-02-26 2020-03-11 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
DE102016113714A1 (en) 2016-07-26 2018-02-01 Rosa Karl Transfection procedure with non-viral gene delivery systems
EP3518931A4 (en) 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
GB201702947D0 (en) 2017-02-23 2017-04-12 Domainex Ltd Novel compounds
CN110862380A (en) * 2019-10-24 2020-03-06 嘉兴特科罗生物科技有限公司 Small molecule compound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034978A2 (en) * 2003-10-02 2005-04-21 Xantos Biomedicine Ag MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF
US20070149469A1 (en) * 2003-10-02 2007-06-28 Christian Korherr Medical use of tbk-1 or of inhibitors thereof
CN1898087A (en) 2003-12-22 2007-01-17 诺沃挪第克公司 Transparent, flexible, impermeable plastic container for storage of pharmaceutical liquids
GB0402809D0 (en) 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds
WO2009030890A1 (en) * 2007-09-03 2009-03-12 University Court Of The University Of Dundee Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma
WO2009103790A2 (en) * 2008-02-21 2009-08-27 Universite Libre De Bruxelles Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-positive and her2-positive subtypes with clinical implications
WO2009122180A1 (en) * 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
GB0903759D0 (en) * 2009-03-04 2009-04-15 Medical Res Council Compound
DE102009019962A1 (en) 2009-05-05 2010-11-11 Merck Patent Gmbh 3 - ([1,2,3] triazol-4-yl) -pyrrolo [2,3-b] pyridine
CA2777762A1 (en) * 2009-10-12 2011-04-21 Myrexis, Inc. Amino - pyrimidine compounds as inhibitors of tbk1 and/or ikk epsilon
GB201012105D0 (en) * 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
DE102010049877A1 (en) 2010-11-01 2012-05-03 Merck Patent Gmbh 7 - ((1,2,3) triazol-4-yl) -pyrrolo (2,3) pyrazine derivatives

Also Published As

Publication number Publication date
WO2013024282A3 (en) 2013-05-16
WO2013024282A2 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
GB201114051D0 (en) Compounds and their uses
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
EP4279087A3 (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer
EA201890768A2 (en) TREATMENT OF MALIGNANT TUMOR INHIBITORS TOR-KINASE
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
BR112014028017A2 (en) compound, pharmaceutical composition, method for treating a disorder, method for reducing the amount of il-17 in an individual, and method for inhibiting ror activity
IN2012DN02018A (en)
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
GEP201706624B (en) Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment
MX348941B (en) Means and methods for treating and/or preventing natural ahr ligand-dependent cancer.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2019001977A (en) Methods and compositions for treating multiple sclerosis and related disorders.
NZ702415A (en) Methods for treating neutropenia using retinoid agonists
ECSP14027393A (en) SYSTEMS AND METHODS TO TREAT AN OPIOID-INDUCED ADVERSE PHARMACODYNAMIC RESPONSE
EA201590744A1 (en) TORRING OF TOR CANCER BY KINASE INHIBITORS
MX2014010940A (en) The use of antithrombin in the treatment of pre-eclampsia.
MX2013010050A (en) Proteasome inhibitor delanzomib for use in the treatment of lupus.
MX2015010296A (en) Treatment of multiple sclerosis with laquinimod.
UA113859C2 (en) SPIROTIENOPIRAN-PIPERIDINE DERIVATIVES AS AN ORL-1 RECEIVER ANTAGONS FOR THEIR APPLICATION IN THE TREATMENT OF ALCOHOLIC DEPENDENCE AND ABUSE
MX2016002307A (en) Cancer treatment.
UY35033A (en) FORMULATION IN TABLETS OF A 3-CINASA PHOSPHYTIDYLINOSITOL INHIBITOR
MX356102B (en) Compounds and methods for treating leukemia.
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)